All News

ACOG 2026: Genevieve Neal-Perry, MD, discussed her clinical experience with elinzanetant for the treatment of VMS associated with menopause.

A nationally representative study found 71.5% of US women aged 21-49 years were open to HPV self-collection, including 9.7 million who were underscreened or never screened.

Hear from the presenting investigator of late-breaking research presented at ACOG 2026 that found over 80% of pregnancy-related infection deaths were preventable.

Hot flashes and night sweats are just 2 of the myriad symptoms associated with menopause. Click through a quick refresher on the transition and effective treatments.

ACOG 2026: In a nationally representative survey, 75% of women with menopausal symptoms reported sleep problems vs 49.8% without symptoms.

New research shows 35.3% of insured individuals with hypertensive disorders of pregnancy had a preventive care visit within 12 months postpartum.

The FDA approved dextromethorphan hydrobromide-bupropion hydrochloride for agitation associated with dementia due to Alzheimer disease.

Discussing how primary care clinicians can approach nutrition conversations with all patients in a non-judgmental, culturally responsive, and behaviorally informed way.

A new oral hair loss pill just cleared phase 2/3 trials. Study investigator Michael Gold, MD, breaks down how VDPHL01 compares to minoxidil and finasteride.

Rachael Sood, NP-C, CDCES, outlines what the FDA clearance of Control-IQ+ for type 1 diabetes in pregnancy means for primary care practice.

6-month INFUSE data show eptinezumab improves migraine outcomes, including headache days and patient-reported measures, even after prior CGRP failures.

Details on 11 key abstracts with clinical relevance for primary care, from menopause management to cervical cancer screening.

The FDA cleared Tandem's Control-IQ+ as the first AID system approved for pregnancy in type 1 diabetes, backed by the CIRCUIT trial.

ACP Internal Medicine Meeting 2026 highlights: new mammography guidelines, AI scribe limitations, and muscle loss risks with GLP-1 weight loss drugs.

WHO’s 2025 kidney health resolution pushes nations to spot CKD earlier, bolster primary care treatment, and expand dialysis and transplant access.

Two-year CAHtalyst Adult data show crinecerfont enabled sustained glucocorticoid dose reductions while maintaining androgen control in classic CAH.

Otarmeni is the first FDA-approved gene therapy for OTOF-related hearing loss, showing rapid hearing gains in the CHORD trial.

Phase 3 data show IL‑33 antibody tozorakimab cuts COPD flare-ups across smokers and low eosinophils, hinting a new biologic option.